22 results on '"Basra, Arti"'
Search Results
2. Evaluation of intermittent preventive treatment of malaria against group B Streptococcus colonization in pregnant women: a nested analysis of a randomized controlled clinical trial of sulfadoxine/pyrimethamine versus mefloquine
- Author
-
Capan-Melser, Mesküre, Mombo Ngoma, Ghyslain, Akerey-Diop, Daisy, Basra, Arti, Würbel, Heike, Groger, Mirjam, Mackanga, Jean R., Zoleko-Manego, Rella, Schipulle, Ulla, Schwing, Julia, Lötsch, Felix, Rehman, Khalid, Matsiegui, Pierre-Blaise, Agnandji, Selidji T., Adegnika, Ayôla A., Bélard, Sabine, González, Raquel, Kremsner, Peter G., Menendez, Clara, and Ramharter, Michael
- Published
- 2015
- Full Text
- View/download PDF
3. In vitro activity of antifungal drugs against Plasmodium falciparum field isolates
- Author
-
Pongratz, Peter, Kurth, Florian, Ngoma, Ghyslain Mombo, Basra, Arti, and Ramharter, Michael
- Published
- 2011
- Full Text
- View/download PDF
4. Loa loa infection in pregnant women, Gabon
- Author
-
Mombo-Ngoma, Ghyslain, Mackanga, Jean Rodolphe, Basra, Arti, Capan, Meskure, Manego, Rella Zoleko, Adegnika, Ayola Akim, Lotsch, Felix, Yazdanbakhsh, Maria, Gonzalez, Raquel, Menendez, Clara, Mabika, Barthelemy, Matsiegui, Pierre Blaise, Kremsner, Peter G., and Ramharter, Michael
- Subjects
Health - Abstract
To the Editor: Loa loa, the African eye worm, is a filarial pathogen of Central African rainforest regions. As of 2013, it had affected an estimated 2-3 million persons in [...]
- Published
- 2015
5. Birth weight, growth, nutritional status and mortality of infants from Lambaréné and Fougamou in Gabon in their first year of life
- Author
-
Zoleko-Manego, Rella, primary, Mischlinger, Johannes, additional, Dejon-Agobé, Jean Claude, additional, Basra, Arti, additional, Mackanga, J. Rodolphe, additional, Akerey Diop, Daisy, additional, Adegnika, Ayola Akim, additional, Agnandji, Selidji T., additional, Lell, Bertrand, additional, Kremsner, Peter G., additional, Matsiegui, Pierre Blaise, additional, González, Raquel, additional, Menendez, Clara, additional, Ramharter, Michael, additional, and Mombo-Ngoma, Ghyslain, additional
- Published
- 2021
- Full Text
- View/download PDF
6. Current status of the clinical development and implementation of paediatric artemisinin combination therapies in Sub-Saharan Africa
- Author
-
Agnandji, Selidji Todagbe, Kurth, Florian, Bélard, Sabine, Mombo-Ngoma, Ghyslain, Basra, Arti, Fernandes, José Francisco, Soulanoudjingar, Solange Solmeheim, Adegnika, Akim Ayola, and Ramharter, Michael
- Published
- 2011
- Full Text
- View/download PDF
7. Pyronaridine: a new ‘old’ drug on the verge of entering the antimalarial armamentarium
- Author
-
Kurth, Florian, Bélard, Sabine, Basra, Arti, and Ramharter, Michael
- Published
- 2011
- Full Text
- View/download PDF
8. Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon
- Author
-
Mombo-Ngoma Ghyslain, Kleine Christian, Basra Arti, Würbel Heike, Diop Daisy A, Capan Mesküre, Adegnika Ayola A, Kurth Florian, Mordmüller Benjamin, Joanny Fanny, Kremsner Peter G, Ramharter Michael, and Bélard Sabine
- Subjects
Malaria ,Ovale ,Malariae ,Artemisinin-combination-therapy ,Artemether-lumefantrine ,Non-falciparum ,Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background The recommendation of artemisinin combination therapy (ACT) as first-line treatment for uncomplicated falciparum malaria is supported by a plethora of high quality clinical trials. However, their recommendation for the treatment of mixed-species malaria and the large-scale use for the treatment of non-falciparum malaria in endemic regions is based on anecdotal rather than systematic clinical evidence. Methods This study prospectively observed the efficacy of artemether-lumefantrine for the treatment of uncomplicated non-falciparum or mixed-species malaria in two routine district hospitals in the Central African country of Gabon. Results Forty patients suffering from uncomplicated Plasmodium malariae, Plasmodium ovale or mixed-species malaria (including Plasmodium falciparum) presenting at the hospital received artemether-lumefantrine treatment and were followed up. All evaluable patients (n = 38) showed an adequate clinical and parasitological response on Day 28 after oral treatment with artemether-lumefantrine (95% confidence interval: 0.91,1). All adverse events were of mild to moderate intensity and completely resolved by the end of study. Conclusions This first systematic assessment of artemether-lumefantrine treatment for P. malariae, P. ovale and mixed-species malaria demonstrated a high cure rate of 100% and a favourable tolerability profile, and thus lends support to the practice of treating non-falciparum or mixed-species malaria, or all cases of malaria without definite species differentiation, with artemether-lumefantrine in Gabon. Trial Registration ClinicalTrials.gov Identifier: NCT00725777
- Published
- 2012
- Full Text
- View/download PDF
9. Population Pharmacokinetics of Mefloquine Intermittent Preventive Treatment for Malaria in Pregnancy in Gabon
- Author
-
Ramharter, Michael, primary, Schwab, Matthias, additional, Mombo-Ngoma, Ghyslain, additional, Zoleko Manego, Rella, additional, Akerey-Diop, Daisy, additional, Basra, Arti, additional, Mackanga, Jean-Rodolphe, additional, Würbel, Heike, additional, Wojtyniak, Jan-Georg, additional, Gonzalez, Raquel, additional, Hofmann, Ute, additional, Geditz, Mirjam, additional, Matsiegui, Pierre-Blaise, additional, Kremsner, Peter G., additional, Menendez, Clara, additional, Kerb, Reinhold, additional, and Lehr, Thorsten, additional
- Published
- 2019
- Full Text
- View/download PDF
10. The use of paediatric artemisinin combinations in sub-Saharan Africa: a snapshot questionnaire survey of health care personnel
- Author
-
Agnandji Selidji T, Kurth Florian, Fernandes Jose F, Soulanoudjingar Solange S, Abossolo Beatrice P, Mombo-Ngoma Ghyslain, Basra Arti, González Raquel, Kizito Gondo, Mayengue Pembe I, Auer-Hackenberg Lorenz, Issifou Saadou, Lell Bertrand, Adegnika Ayola A, and Ramharter Michael
- Subjects
Artemisinin based combinations therapy ,Paediatric drug formulation ,Artemether ,Lumefantrine ,Amodiaquine ,Dihydroartemisinin ,Piperaquine ,Mefloquine ,Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Paediatric drug formulations for artemisinin combination therapy (P-ACT) have been developed over the past few years and have been shown to improve the therapeutic management of young children with uncomplicated falciparum malaria. This process was however not equally paralleled by a timely adoption of P-ACT in national and international treatment recommendations. National malaria programmes in sub-Saharan Africa have not yet widely embraced this new therapeutic tool. To which extent P-ACT is used in the field in sub-Saharan Africa is not known to date. Methods This snapshot questionnaire survey aimed to provide an overview on the current routine practices for the availability and use of P-ACT as anti-malarial treatment for young children in sub-Saharan Africa. Health care personnel in seven countries in West-, Central, and East-Africa were invited to answer a structured questionnaire assessing use and availability of P-ACT. Results A total of 71 respondents including doctors, nurses and pharmacy personnel responsible for the anti-malarial treatment of young children were interviewed. P-ACT was used by 83% (95% confidence interval: 73-90%; n = 59) as first-line treatment for young children. Use of 15 different P-ACT products was reported among which only two have received WHO prequalification status and approval by a stringent registration authority. Use of a specific P-ACT product was not linked to consumer prices or availability of supporting clinical trial data, but may depend more on the marketing capacity of the manufacturer. Major differences in frequency and dosing of anti-malarial regimens with identical anti-malarial compounds and the marketing of loose combinations were recorded. Conclusion Paediatric ACT is widely used for the treatment of uncomplicated malaria in young children. However, the majority of P-ACT formulations in use do not meet highest international quality standards evoking concerns for patients' safety and the induction of drug resistance. Improving the quality of currently marketed P-ACT should constitute a public health priority besides their adoption into official treatment recommendations.
- Published
- 2011
- Full Text
- View/download PDF
11. Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-negative women: a multicentre randomized controlled trial
- Author
-
Gonzalez, Raquel, Mombo-Ngoma, Ghyslain, Ouedraogo, Smaila, Kakolwa, Mwaka A., Abdulla, Salim, Accrombessi, Manfred, Aponte, John J., Akerey-Diop, Daisy, Basra, Arti, Briand, Valerie, Capan, Meskure, Cot, Michel, Kabanywanyi, Abdunoor M., Kleine, Christian, Kremsner, Peter G., Macete, Eusebio, Mackanga, Jean-Rodolphe, Massougbodgi, Achille, Mayor, Alfredo, Nhacolo, Arsenio, Pahlavan, Golbahar, Ramharter, Michael, Ruperez, Maria, Sevene, Esperanca, Vala, Anifa, Zoleko- Manego, Rella, and Menendez, Clara
- Subjects
Mefloquine -- Health aspects ,Malaria -- Prevention -- Care and treatment ,HIV patients -- Health aspects -- Care and treatment ,Pregnant women -- Drug therapy -- Comparative analysis -- Health aspects -- Care and treatment ,Biological sciences - Abstract
Background: Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended by WHO to prevent malaria in African pregnant women. The spread of SP parasite resistance has raised concerns regarding long-term use for IPT. Mefloquine (MQ) is the most promising of available alternatives to SP based on safety profile, long half-life, and high efficacy in Africa. We evaluated the safety and efficacy of MQ for IPTp compared to those of SP in HIV-negative women. Methods and Findings: A total of 4,749 pregnant women were enrolled in an open-label randomized clinical trial conducted in Benin, Gabon, Mozambique, and Tanzania comparing two-dose MQ or SP for IPTp and MQ tolerability of two different regimens. The study arms were: (1) SP, (2) single dose MQ (15 mg/kg), and (3) split-dose MQ in the context of long lasting insecticide treated nets. There was no difference on low birth weight prevalence (primary study outcome) between groups (360/2,778 [13.0%]) for MQ group and 177/1,398 (12.7%) for SP group; risk ratio [RR], 1.02 (95% CI 0.86-1.22; p = 0.80 in the ITT analysis). Women receiving MQ had reduced risks of parasitemia (63/1,372 [4.6%] in the SP group and 88/2,737 [3.2%] in the MQgroup; RR, 0.70 [95% CI 0.51-0.96]; p = 0.03) and anemia at delivery (609/1,380 [44.1%] in the SP group and 1,110/2743 [40.5%] in the MQ group; RR, 0.92 [95% CI 0.85-0.99]; p = 0.03), and reduced incidence of clinical malaria (96/ 551.8 malaria episodes person/year [PYAR] in the SP group and 130/1,103.2 episodes PYAR in the MQ group; RR, 0.67 [95% CI 0.52-0.88]; p = 0.004) and all-cause outpatient attendances during pregnancy (850/557.8 outpatients visits PYAR in the SP group and 1,480/1,110.1 visits PYAR in the MQ group; RR, 0.86 [0.78-0.95]; p = 0.003). There were no differences in the prevalence of placental infection and adverse pregnancy outcomes between groups. Tolerability was poorer in the two MQ groups compared to SP. The most frequently reported related adverse events were dizziness (ranging from 33.9% to 35.5% after dose 1; and 16.0% to 20.8% after dose 2) and vomiting (30.2% to 31.7%, after dose 1 and 15.3% to 17.4% after dose 2) with similar proportions in the full and split MQ arms. The open-label design is a limitation of the study that affects mainly the safety assessment. Conclusions: Women taking MQ IPTp (15 mg/kg) in the context of long lasting insecticide treated nets had similar prevalence rates of low birth weight as those taking SP IPTp. MQ recipients had less clinical malaria than SP recipients, and the pregnancy outcomes and safety profile were similar. MQ had poorer tolerability even when splitting the dose over two days. These results do not support a change in the current IPTp policy. Trial registration: ClinicalTrials.gov NCT 00811421; Pan African Clinical Trials Registry PACTR 2010020001429343 Please see later in the article for the Editors' Summary., Introduction As the scourge of malaria continues, special considerations regarding the management of the infection in the most vulnerable groups are needed to achieve maximum safety and efficacy of control [...]
- Published
- 2014
- Full Text
- View/download PDF
12. Intermittent Preventive Treatment of Malaria in Pregnancy with Mefloquine in HIV-Infected Women Receiving Cotrimoxazole Prophylaxis: A Multicenter Randomized Placebo-Controlled Trial
- Author
-
González, Raquel, Mombo-Ngoma, Ghyslain, Ouédraogo, Smaïla, Kakolwa, Mwaka A., Abdulla, Salim, Accrombessi, Manfred, Aponte, John J., Akerey-Diop, Daisy, Basra, Arti, Briand, Valérie, Capan, Meskure, Cot, Michel, Kabanywanyi, Abdunoor M., Kleine, Christian, Kremsner, Peter G., Macete, Eusebio, Mackanga, Jean-Rodolphe, Massougbodgi, Achille, Mayor, Alfredo, Nhacolo, Arsenio, Pahlavan, Golbahar, Ramharter, Michael, Rupérez, María, Sevene, Esperança, Vala, Anifa, Zoleko-Manego, Rella, and Menéndez, Clara
- Subjects
Infectious Disease Control ,Epidemiology ,Maternal Health ,Biology and Life Sciences ,Plant Science ,Plant Pathology ,Infectious Disease Epidemiology ,Malaria ,Infectious Diseases ,Antenatal Care ,Pregnancy ,parasitic diseases ,Medicine and Health Sciences ,Parasitic Diseases ,Women's Health ,Research Article - Abstract
Clara Menéndez and colleagues conducted an open-label randomized controlled trial in HIV-negative pregnant women in Benin, Gabon, Mozambique, and Tanzania to evaluate the safety and efficacy of mefloquine compared to sulfadoxine-pyrimethamine for intermittent preventative therapy for malaria. Please see later in the article for the Editors' Summary, Background Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended by WHO to prevent malaria in African pregnant women. The spread of SP parasite resistance has raised concerns regarding long-term use for IPT. Mefloquine (MQ) is the most promising of available alternatives to SP based on safety profile, long half-life, and high efficacy in Africa. We evaluated the safety and efficacy of MQ for IPTp compared to those of SP in HIV-negative women. Methods and Findings A total of 4,749 pregnant women were enrolled in an open-label randomized clinical trial conducted in Benin, Gabon, Mozambique, and Tanzania comparing two-dose MQ or SP for IPTp and MQ tolerability of two different regimens. The study arms were: (1) SP, (2) single dose MQ (15 mg/kg), and (3) split-dose MQ in the context of long lasting insecticide treated nets. There was no difference on low birth weight prevalence (primary study outcome) between groups (360/2,778 [13.0%]) for MQ group and 177/1,398 (12.7%) for SP group; risk ratio [RR], 1.02 (95% CI 0.86–1.22; p = 0.80 in the ITT analysis). Women receiving MQ had reduced risks of parasitemia (63/1,372 [4.6%] in the SP group and 88/2,737 [3.2%] in the MQ group; RR, 0.70 [95% CI 0.51–0.96]; p = 0.03) and anemia at delivery (609/1,380 [44.1%] in the SP group and 1,110/2743 [40.5%] in the MQ group; RR, 0.92 [95% CI 0.85–0.99]; p = 0.03), and reduced incidence of clinical malaria (96/551.8 malaria episodes person/year [PYAR] in the SP group and 130/1,103.2 episodes PYAR in the MQ group; RR, 0.67 [95% CI 0.52–0.88]; p = 0.004) and all-cause outpatient attendances during pregnancy (850/557.8 outpatients visits PYAR in the SP group and 1,480/1,110.1 visits PYAR in the MQ group; RR, 0.86 [0.78–0.95]; p = 0.003). There were no differences in the prevalence of placental infection and adverse pregnancy outcomes between groups. Tolerability was poorer in the two MQ groups compared to SP. The most frequently reported related adverse events were dizziness (ranging from 33.9% to 35.5% after dose 1; and 16.0% to 20.8% after dose 2) and vomiting (30.2% to 31.7%, after dose 1 and 15.3% to 17.4% after dose 2) with similar proportions in the full and split MQ arms. The open-label design is a limitation of the study that affects mainly the safety assessment. Conclusions Women taking MQ IPTp (15 mg/kg) in the context of long lasting insecticide treated nets had similar prevalence rates of low birth weight as those taking SP IPTp. MQ recipients had less clinical malaria than SP recipients, and the pregnancy outcomes and safety profile were similar. MQ had poorer tolerability even when splitting the dose over two days. These results do not support a change in the current IPTp policy. Trial registration ClinicalTrials.gov NCT 00811421; Pan African Clinical Trials Registry PACTR 2010020001429343 Please see later in the article for the Editors' Summary, Editors' Summary Background Half the world's population is at risk of malaria, a mosquito-borne parasitic disease that kills about 600,000 people every year. Most of these deaths occur among young children in sub-Saharan Africa but pregnant women and their unborn children living in Africa are also very vulnerable to malaria. Infection with malaria during pregnancy can cause severe maternal anemia (reduced red blood cell numbers), stillbirths, and pre-term and low-birthweight babies, and is responsible for the deaths of many African babies and women. To prevent this loss of life, the World Health Organization (WHO) recommends a three-pronged approach—the delivery to pregnant women of the antimalarial drug sulfadoxine-pyrimethamine (SP) at each scheduled antenatal care visit given at least one month apart (intermittent preventive treatment in pregnancy; IPTp), the use of insecticide treated bed nets to protect pregnant women from the bites of infected mosquitoes, and effective case management of pregnant women with malarial illness. Why Was This Study Done? IPTp with SP reduces the delivery of low-birth-weight babies and neonatal deaths but malaria parasites are becoming resistant to SP. Thus, other antimalarial drugs need to be evaluated for use in IPTp. Suitable drugs need to remain in the body for a long time to maximize their prophylactic (preventative) effect, they need to be given as a single dose at antenatal clinic visits to ensure compliance, and they must not harm the unborn child. In this open-label, randomized controlled trial (RCT), the researchers compare the efficacy and safety of IPTp with SP and mefloquine (MQ, an antimalarial drug that matches these criteria) in HIV-negative women living in Africa. The study also compares the tolerability of two MQ regimens. RCTs compare outcomes in groups of people chosen to receive different interventions through the play of chance; in open-label RCTs, both the researchers and the study participants know which treatment is being administered. IPTp with SP is only recommended for HIV-negative women because SP interacts with cotrimoxazole, which is routinely given to HIV-positive individuals to prevent infections. What Did the Researchers Do and Find? The researchers assigned 4,749 pregnant women in Benin, Gabon, Mozambique, and Tanzania to one of three study groups. Participants in the SP and MQ groups received two doses of SP or MQ, respectively, administered at least one month apart. Participants in the split-dose MQ group received each MQ dose as half doses given on consecutive days. The prevalence of low-birth-weight deliveries (the study's primary outcome; the prevalence of a condition is the proportion of a population with that condition) was similar in the SP group and in the combined MQ groups. However, compared to women who received SP, women who received MQ had a lower risk of parasitemia (parasites in the blood), a lower risk of anemia at delivery, fewer episodes of clinical malaria, and fewer outpatient attendances. The prevalence of placental infection with malaria parasites and of adverse pregnancy outcomes such as stillbirth was similar in all the study groups. Finally, the tolerability of IPTp was poorer in the two MQ intervention groups than in the SP group, but similar proportions of adverse events (mainly dizziness and vomiting) were reported for the two MQ dosing regimens. What Do These Findings Mean? These findings indicate that HIV-negative African women taking MQ for IPTp had a similar risk of a low-birth-weight delivery (the study's primary outcome) and lower risk of malaria illness during pregnancy than women taking SP for IPTp. Because the study did not have a no-IPTp arm (for ethical reasons), these findings provide no information about the efficacy or safety or either MQ or SP per se; these findings only indicate that MQ is no more efficacious than SP in the prevention of low-birth-weight babies. Moreover, because the study was open-label, the accuracy of the findings related to the tolerability and safety of MQ compared to SP may be limited because of biases in the assessment of safety outcomes. Given that the MQ dose used here for IPTp was associated with poorer tolerability than that of SP, these findings do not support the use of MQ instead of SP for IPTp. Additional Information Please access these websites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.1001733. A related PLOS Medicine Research Article by Raquel González and colleagues examines IPTp-MQ in HIV-infected women receiving cotrimoxazole prophylaxis This study is further discussed in a PLOS Medicine Perspective by Richard Steketee. Information is available from the World Health Organization on malaria (in several languages) and on malaria in pregnancy; information on IPTp and the updated WHO policy recommendation on IPTp with SP are available; the 2013 World Malaria Report provides details of the current global malaria situation The US Centers for Disease Control and Prevention also provides information on malaria; a personal story about malaria in pregnancy is available Information is available from the Roll Back Malaria Partnership on all aspects of global malaria control, including information on malaria in pregnancy The Malaria in Pregnancy Consortium is undertaking research into the prevention and treatment of malaria in pregnancy MedlinePlus provides links to additional information on malaria (in English and Spanish)
- Published
- 2014
13. Young adolescent girls are at high risk for adverse pregnancy outcomes in sub-Saharan Africa: an observational multicountry study
- Author
-
Mombo-Ngoma, Ghyslain, primary, Mackanga, Jean Rodolphe, additional, González, Raquel, additional, Ouedraogo, Smaila, additional, Kakolwa, Mwaka A, additional, Manego, Rella Zoleko, additional, Basra, Arti, additional, Rupérez, María, additional, Cot, Michel, additional, Kabanywany, Abdunoor M, additional, Matsiegui, Pierre-Blaise, additional, Agnandji, Seldiji T, additional, Vala, Anifa, additional, Massougbodji, Achille, additional, Abdulla, Salim, additional, Adegnika, Ayôla A, additional, Sevene, Esperança, additional, Macete, Eusebio, additional, Yazdanbakhsh, Maria, additional, Kremsner, Peter G, additional, Aponte, John J, additional, Menéndez, Clara, additional, and Ramharter, Michael, additional
- Published
- 2016
- Full Text
- View/download PDF
14. 1225
- Author
-
Meyer, Brigitte, primary, Basra, Arti, additional, Aberle, Stephan, additional, Aberle, Judith, additional, Robibaro, Bruno, additional, Wenisch, Christoph, additional, and Laferl, Hermann, additional
- Published
- 2015
- Full Text
- View/download PDF
15. Epidemiology of Human Herpes Virus 8 in Pregnant Women and their Newborns - A cross-sectional delivery survey in Central Gabon
- Author
-
Capan-Melser, Mesküre, primary, Mombo-Ngoma, Ghyslain, additional, Akerey-Diop, Daisy, additional, Basra, Arti, additional, Manego-Zoleko, Rella, additional, Würbel, Heike, additional, Lötsch, Felix, additional, Groger, Mirjam, additional, Skoll, Michael, additional, Schwing, Julia, additional, Schipulle, Ulla, additional, Matsiegui, Pierre-Blaise, additional, González, Raquel, additional, Menendez, Clara, additional, Kremsner, Peter G., additional, Adegnika, Ayôla A., additional, Agnandji, Selidji T., additional, and Ramharter, Michael, additional
- Published
- 2015
- Full Text
- View/download PDF
16. Loa loaInfection in Pregnant Women, Gabon
- Author
-
Mombo-Ngoma, Ghyslain, primary, Mackanga, Jean Rodolphe, additional, Basra, Arti, additional, Capan, Meskure, additional, Manego, Rella Zoleko, additional, Adegnika, Ayôla Akim, additional, Lötsch, Felix, additional, Yazdanbakhsh, Maria, additional, González, Raquel, additional, Menendez, Clara, additional, Mabika, Barthelemy, additional, Matsiegui, Pierre Blaise, additional, Kremsner, Peter G., additional, and Ramharter, Michael, additional
- Published
- 2015
- Full Text
- View/download PDF
17. Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon
- Author
-
Mombo-Ngoma, Ghyslain, Kleine, Christian, Basra, Arti, Würbel, Heike, Diop, Daisy A., Capan, Mesküre, Adegnika, Ayola A., Kurth, Florian Michael, Mordmüller, Benjamin Gottlieb, Joanny, Fanny, Kremsner, Peter G., Ramharter, Michael, Bélard, Sabine, Mombo-Ngoma, Ghyslain, Kleine, Christian, Basra, Arti, Würbel, Heike, Diop, Daisy A., Capan, Mesküre, Adegnika, Ayola A., Kurth, Florian Michael, Mordmüller, Benjamin Gottlieb, Joanny, Fanny, Kremsner, Peter G., Ramharter, Michael, and Bélard, Sabine
- Abstract
Background: The recommendation of artemisinin combination therapy (ACT) as first-line treatment for uncomplicated falciparum malaria is supported by a plethora of high quality clinical trials. However, their recommendation for the treatment of mixed-species malaria and the large-scale use for the treatment of non-falciparum malaria in endemic regions is based on anecdotal rather than systematic clinical evidence. Methods: This study prospectively observed the efficacy of artemether-lumefantrine for the treatment of uncomplicated non-falciparum or mixed-species malaria in two routine district hospitals in the Central African country of Gabon. Results: Forty patients suffering from uncomplicated Plasmodium malariae, Plasmodium ovale or mixed-species malaria (including Plasmodium falciparum) presenting at the hospital received artemether-lumefantrine treatment and were followed up. All evaluable patients (n = 38) showed an adequate clinical and parasitological response on Day 28 after oral treatment with artemether-lumefantrine (95% confidence interval: 0.91,1). All adverse events were of mild to moderate intensity and completely resolved by the end of study. Conclusions: This first systematic assessment of artemether-lumefantrine treatment for P. malariae, P. ovale and mixed-species malaria demonstrated a high cure rate of 100% and a favourable tolerability profile, and thus lends support to the practice of treating non-falciparum or mixed-species malaria, or all cases of malaria without definite species differentiation, with artemether-lumefantrine in Gabon. Trial Registration: ClinicalTrials.gov Identifier: NCT00725777
- Published
- 2012
18. Efficacy of Mefloquine Intermittent Preventive Treatment in Pregnancy Against Schistosoma haematobium Infection in Gabon: A Nested Randomized Controlled Assessor-Blinded Clinical Trial
- Author
-
Basra, Arti, primary, Mombo-Ngoma, Ghyslain, additional, Capan Melser, Meskure, additional, Akerey Diop, Daisy, additional, Würbel, Heike, additional, Mackanga, Jean-Rodolphe, additional, Fürstenau, Moritz, additional, Manego Zoleko, Rella, additional, Adegnika, Ayola A., additional, Gonzalez, Raquel, additional, Menendez, Clara, additional, Kremsner, Peter G., additional, and Ramharter, Michael, additional
- Published
- 2012
- Full Text
- View/download PDF
19. Pyronaridine–artesunate combination therapy for the treatment of malaria
- Author
-
Kurth, Florian, primary, Bélard, Sabine, additional, Basra, Arti, additional, and Ramharter, Michael, additional
- Published
- 2011
- Full Text
- View/download PDF
20. MORTALITY, MORBIDITY AND DEVELOPMENTAL OUTCOMES IN CHILDREN BORN TO WOMEN RECEIVING EITHER MEFLOQUINE OR SULPHADOXINE-PYRIMETHAMINE AS INTERMITTENT PREVENTIVE TREATMENT OF MALARIA IN PREGNANCY: A RANDOMIZED CONTROLLED TRIAL
- Author
-
Ruperez, Maria, Gonzalez, Raquel, Mombo-Ngoma, Ghyslain, Ouedraogo, Smaila, Kakolwa, Mwaka A., Abdulla, Salim, Accrombessi, Manfred, Aponte, John J., Akerey-Diop, Daisy, Basra, Arti, Briand, Valerie, Capan, Meskure, Cot, Michel, Kabanywanyi, Abdunoor M., Kleine, Christian, Kremsner, Peter G., Macete, Eusebio, Mackanga, Jean-Rodolphe, Massougbodgi, Achille, Mayor, Alfredo, Nhacolo, Arsenio, Pahlavan, Golbahar, Ramharter, Michael, Esperanca Sevene, Vala, Anifa, Zoleko-Manego, Rella, and Menendez, Clara
21. Population Pharmacokinetics of Mefloquine Intermittent Preventive Treatment for Malaria in Pregnancy in Gabon
- Author
-
Ramharter, Michael, Schwab, Matthias, Mombo-Ngoma, Ghyslain, Zoleko Manego, Rella, Akerey-Diop, Daisy, Basra, Arti, Mackanga, Jean-Rodolphe, Würbel, Heike, Wojtyniak, Jan-Georg, Gonzalez, Raquel, Hofmann, Ute, Geditz, Mirjam, Matsiegui, Pierre-Blaise, Kremsner, Peter G., Menendez, Clara, Kerb, Reinhold, and Lehr, Thorsten
- Abstract
Mefloquine was evaluated as an alternative for intermittent preventive treatment of malaria in pregnancy (IPTp) due to increasing resistance against the first-line drug sulfadoxine-pyrimethamine (SP). This study determined the pharmacokinetic characteristics of the mefloquine stereoisomers and the metabolite carboxymefloquine (CMQ) when given as IPTp in pregnant women.
- Published
- 2018
- Full Text
- View/download PDF
22. Efficacy of Mefloquine Intermittent Preventive Treatment in Pregnancy Against Schistosoma haematobium Infection in Gabon: A Nested Randomized Controlled Assessor-Blinded Clinical Trial.
- Author
-
Basra, Arti, Mombo-Ngoma, Ghyslain, Capan Melser, Meskure, Akerey Diop, Daisy, Würbel, Heike, Mackanga, Jean-Rodolphe, Fürstenau, Moritz, Manego Zoleko, Rella, Adegnika, Ayola A., Gonzalez, Raquel, Menendez, Clara, Kremsner, Peter G., and Ramharter, Michael
- Subjects
- *
MEFLOQUINE , *DRUG efficacy , *PREGNANCY , *SCHISTOSOMA haematobium , *RANDOMIZED controlled trials , *DRUG administration , *MALARIA prevention - Abstract
Mefloquine—currently investigated as preventive treatment against malaria in pregnancy—was found to lead to a 98% reduction of Schistosoma haematobium egg excretion in pregnant women, indicating its potential usefulness for the prevention of both malaria and schistosomiasis.Background. Urogenital schistosomiasis is a major public health problem in sub-Saharan Africa, and routine programs for screening and treatment of pregnant women are not established. Mefloquine—currently evaluated as a potential alternative to sulfadoxine-pyrimethamine as intermittent preventive treatment against malaria in pregnancy (IPTp)—is known to exhibit activity against Schistosoma haematobium. In this study we evaluated the efficacy of mefloquine IPTp against S. haematobium infection in pregnant women.Methods. Pregnant women with S. haematobium infection presenting at 2 antenatal health care centers in rural Gabon were invited to participate in this nested randomized controlled, assessor-blinded clinical trial comparing sulfadoxine-pyrimethamine with mefloquine IPTp. Study drugs were administered twice during pregnancy with a 1- month interval after completion of the first trimester.Results. Sixty-five pregnant women were included in this study. Schistosoma haematobium egg excretion rates showed a median reduction of 98% (interquartile range [IQR], 70%–100%) in the mefloquine group compared to an increase of 20% (IQR, −186% to 75%) in the comparator group. More than 80% of patients showed at least 50% reduction of egg excretion and overall cure rate was 47% (IQR, 36%–70%) 6 weeks after the second administration of mefloquine IPTp.Conclusion. When used as IPTp for the prevention of malaria, mefloquine shows promising activity against concomitant S. haematobium infection leading to an important reduction of egg excretion in pregnant women. Provided that further studies confirm these findings, the use of mefloquine may transform future IPTp programs into a 2-pronged intervention addressing 2 of the most virulent parasitic infections in pregnant women in sub-Saharan Africa.Clinical Trials Registration. NCT01132248; ATMR2010020001429343. [ABSTRACT FROM PUBLISHER]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.